Pharmigene was awarded the 12th National Innovation Award
Premier of Executive Yuan, CHANG San-cheng, awarded Pharmigene, Inc. the 12th National Innovation Award on December 24th in the W Hotel, Taipei, for Pharmigene's Gene Detection kit for Adverse Drug Reactions, PG5801 and PG1502.
The tests are being designed for use in detecting the presence of key genetic alleles in individual patients being considered for treatment with drugs that have been linked to the development of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
Lots of academic studies have demonstrated the strong association of Human Leukocyte Antigen (HLA-B*5801, HLA-B*1502) and allopurinol, carbamazepine, phenytoin, & oxcarbazepine induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Individuals that use DNA tests to determine their HLA genotypes prior to taking these drugs can reduce their risks of developing SJS/TEN significantly.